Literature DB >> 29112733

Goserelin does not preserve ovarian function against chemotherapy-induced damage.

K Oktay1, E Taylan2, K A Rodriguez-Wallberg3, G Bedoschi4, V Turan5, F Pacheco6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29112733      PMCID： PMC5834055          DOI： 10.1093/annonc/mdx695

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

1.  Control of follicle-stimulating hormone by estradiol and the inhibins: critical role of estradiol at the hypothalamus during the luteal-follicular transition.

Authors:  Corrine K Welt; Yanira L Pagan; Patricia C Smith; Kimberly B Rado; Janet E Hall
Journal:  J Clin Endocrinol Metab       Date:  2003-04       Impact factor: 5.958

2.  Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging.

Authors:  Siobán D Harlow; Margery Gass; Janet E Hall; Roger Lobo; Pauline Maki; Robert W Rebar; Sherry Sherman; Patrick M Sluss; Tobie J de Villiers
Journal:  J Clin Endocrinol Metab       Date:  2012-02-16       Impact factor: 5.958

3.  Appraising the Biological Evidence for and Against the Utility of GnRHa for Preservation of Fertility in Patients With Cancer.

Authors:  Kutluk Oktay; Giuliano Bedoschi
Journal:  J Clin Oncol       Date:  2016-05-23       Impact factor: 44.544

4.  No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial.

Authors:  Isabelle Demeestere; Pauline Brice; Fedro A Peccatori; Alain Kentos; Jehan Dupuis; Pierre Zachee; Olivier Casasnovas; Eric Van Den Neste; Julie Dechene; Viviane De Maertelaer; Dominique Bron; Yvon Englert
Journal:  J Clin Oncol       Date:  2016-05-23       Impact factor: 44.544

5.  GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial.

Authors:  R C F Leonard; D J A Adamson; G Bertelli; J Mansi; A Yellowlees; J Dunlop; G A Thomas; R E Coleman; R A Anderson
Journal:  Ann Oncol       Date:  2017-08-01       Impact factor: 32.976
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.